SI-BONE/$SIBN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About SI-BONE
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
- Ticker
- $SIBN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 376
- Headquarters
- Santa Clara, United States
- Website
- si-bone.com
SI-BONE Metrics
BasicAdvanced
$1.1B
-
-$0.31
0.62
-
Price and volume
Market cap
$1.1B
Beta
0.62
52-week high
$25.92
52-week low
$11.48
Average daily volume
790K
Financial strength
Current ratio
7.585
Quick ratio
6.001
Long term debt to equity
0.23
Total debt to equity
0.232
Interest coverage (TTM)
-6.88%
Profitability
EBITDA (TTM)
-10.085
Gross margin (TTM)
79.40%
Net profit margin (TTM)
-6.20%
Operating margin (TTM)
-7.57%
Revenue per employee (TTM)
$590,000
Management effectiveness
Return on assets (TTM)
-4.25%
Return on equity (TTM)
-7.67%
Valuation
Price to revenue (TTM)
4.864
Price to book
5.9
Price to tangible book (TTM)
5.9
Price to free cash flow (TTM)
-255.878
Free cash flow yield (TTM)
-0.39%
Free cash flow per share (TTM)
-0.095
Growth
Revenue change (TTM)
13.99%
Earnings per share change (TTM)
-39.46%
3-year revenue growth (CAGR)
18.69%
3-year earnings per share growth (CAGR)
-35.96%
What the Analysts think about SI-BONE
Analyst ratings (Buy, Hold, Sell) for SI-BONE stock.
Analyst projections of the future price of SI-BONE stock.
Bulls say / Bears say
Third-quarter revenue grew 14.5%, while US procedure volume rose about 20% and the active US physician base grew 16%. SI-BONE also reported positive adjusted EBITDA and operating cash flow, pointing to improving operating leverage. (GlobeNewswire)
FDA clearance for iFuse Granite Onyx lets SI-BONE enter spine fusion failures beyond its traditional pelvic focus. The company estimates the device targets a $1.5 billion annual market, creating room for growth if adoption develops. (GlobeNewswire, The Motley Fool)
New hospital payment classifications for complex spinal fusions using iFuse Bedrock Granite took effect in October, with payments increasing by up to about $50,000 per qualifying procedure. Better reimbursement could make hospitals more willing to use the product. (GlobeNewswire)
Third-quarter revenue growth of 14.5% was below the more than 20% growth implied by full-year guidance for the fourth quarter. US procedure volume grew faster than revenue, as a shift in procedure mix and care settings reduced average selling price. (GlobeNewswire, The Motley Fool)
SI-BONE remains loss-making, with a third-quarter net loss of $3.6 million. Management also expects some gross-margin pressure in 2027 as it adds capacity to support the Onyx launch. (GlobeNewswire, The Motley Fool)
A Department of Justice investigation into payments to healthcare professionals remains unresolved, and SI-BONE disclosed a recall of 98 implants after packaging may have failed to preserve sterility. Any adverse regulatory findings or wider recall could add legal, cost and reputational risk. (SEC, StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
SI-BONE Financial Performance
Revenues and expenses
SI-BONE Earnings Performance
Company profitability
Upcoming events
No upcoming events
SI-BONE News
AllArticlesVideos
Funds containing SI-BONE
Fund name | Fund size | $SIBN weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.10% |
iShares Ageing Population£AGES | $953M | 0.10% |
iShares Ageing Population€AGED | $903M | 0.10% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.